Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant improvement in overall survival (OS), according to updated results from a large ...

Last June, Patricia Hart — now 59 years — heard words no one wants to hear: triple-negative invasive ductal carcinoma. Her care team was frank about the danger: This form of breast cancer is ...

The report is based on the experience of a patient with recurrent retroperitoneal DDLPS and is believed to be the first reported case in which such a patient achieved a pathological complete response ...

A novel vaccine, currently under trial at the Cleveland Clinic, offers potential in preventing aggressive triple-negative breast cancer recurrences and initial development.

The FDA approved pembrolizumab (Keytruda) plus carboplatin and paclitaxel, followed by single-agent pembrolizumab, in adult patients with primary advanced or recurrent endometrial carcinoma. The ...